Abstract
Prostate-specific membrane antigen (PSMA) theranostics has been a momentous triumph for nuclear medicine. The recent approvals of PSMA-targeted imaging agents (68Ga-PSMA-11, 18F-DCFPyL) and radiopharmaceutical therapy (177Lu-PSMA-617) have paved the way for theranostics as a viable care strategy for men with metastatic castration-resistant prostate cancer. The imaging clinical trials OSPREY, CONDOR and those conducted at the University of California (Los Angeles and San Francisco) as well as the randomized phase 3 therapy trial VISION have been the fruitful beginnings for PSMA theranostics. There are currently several ongoing clinical trials to expand the reach of PSMA theranostics to the earlier phases of prostate cancer and to optimize its utility in combination therapeutic regimens. We provide a brief narrative review of the many PSMA-directed radiopharnaecutical therapy clinical trials with the beta emitter, 177Lu-PSMA-617, and the alpha emitter, 225Ac-PSMA-617, in prostate cancer.
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
SNMMI members
SNMMI Member login is currently down. For immediate access to the journals, visit https://jnm.snmjournals.org and https://tech.snmjournals.org.
Individuals
Login as an individual user